Is retatrutide a peptide?

Yes. It is a lab-made peptide designed to activate three hormone receptors: GIP, GLP-1 and glucagon.

How is retatrutide different from semaglutide?

Semaglutide acts on the GLP-1 receptor only and is an approved medicine. Retatrutide also acts on the GIP and glucagon receptors and is still investigational.

Has retatrutide been tested in humans?

Yes, in clinical trials. Phase 2 trials in obesity and type 2 diabetes have been published, and results from larger phase 3 trials began to be reported in late 2025 and 2026. It is still investigational.

What are the side effects of retatrutide?

In trials, the most common were nausea, diarrhea, vomiting and constipation. Some participants also had increases in heart rate or dysesthesia, an altered sense of touch on the skin. Long-term effects are not yet known.

Retatrutide Peptide: What It Is, How It Works and Side Effects

What is retatrutide?

Retatrutide is a single lab-made peptide designed to act on three receptors. Two of them respond to incretins, the gut hormones GIP and GLP-1 that are released after eating. The third is the receptor for glucagon, a pancreas hormone best known for raising blood sugar between meals. Because it acts on all three, researchers call it a triple agonist. It was designed to last much longer in the body than the natural hormones.

Retatrutide is investigational and in large clinical trials as of 2026. Its developer, Eli Lilly, also makes tirzepatide, an approved drug that acts on two of the same receptors. Retatrutide is often discussed as the next step in that line of research, but its long-term safety and benefits are still being tested.

How does retatrutide work?

Each receptor does something different. GLP-1 receptor activation increases insulin release when blood sugar is high, slows stomach emptying and acts on brain areas that control appetite. GIP is the other main incretin hormone. Researchers think activating its receptor adds to the effects on insulin and appetite, although exactly how is still debated.

Glucagon receptor activation is the unusual part. In animal and early human research, glucagon signaling increased energy use and fat breakdown in the liver. On its own, glucagon raises blood sugar. The idea behind retatrutide is that the GLP-1 and GIP effects offset this, while the extra energy use and liver effects remain. How much each receptor contributes in people is still being worked out.

Mixing it for research?

Retatrutide reconstitution chart: how much bacteriostatic water to add to a 5 mg, 10 mg or 20 mg vial and how many units each amount is, with Matthew’s step-by-step video.

See the mixing chart

What has research looked at?

Obesity: A phase 2 trial in adults with obesity or overweight, published in 2023, found that participants on retatrutide lost much more weight on average than those on placebo over 48 weeks.
Type 2 diabetes: A separate phase 2 trial in people with type 2 diabetes reported lower HbA1c, a measure of average blood sugar, and lower body weight compared with placebo.
Liver fat: In a substudy of the obesity trial, participants with fatty liver disease had large drops in liver fat, and many reached levels considered normal.
Heart and metabolic markers: Trials reported changes in blood pressure, blood fats and other markers. Whether retatrutide reduces heart attacks or strokes has not been shown.
Phase 3 trials: Since late 2025, Eli Lilly has reported results, not all yet fully published, from several phase 3 TRIUMPH trials in people with obesity, including people with knee osteoarthritis, type 2 diabetes or heart disease. Participants on retatrutide lost more weight on average than those on placebo.

The evidence is growing but still early. Much of the detailed published data comes from phase 2 trials that lasted about a year and included a few hundred participants each. The phase 3 trials are larger and longer, but still lasted about one to two years, so they cannot settle long-term safety or show what happens over many years.

Semaglutide vs tirzepatide vs retatrutide

These three drugs are often compared. Semaglutide (Ozempic, Wegovy) acts on the GLP-1 receptor only. Tirzepatide (Mounjaro, Zepbound) acts on the GLP-1 and GIP receptors. Retatrutide adds the glucagon receptor. Semaglutide and tirzepatide are approved medicines with years of data, while retatrutide is still investigational. Results from separate trials with different participants cannot be compared directly, so claims that one drug is stronger should be read with care.

Side effects and cautions

In trials, the most common side effects were digestive: nausea, diarrhea, vomiting and constipation. Most were mild to moderate and happened more often early in treatment, though some participants stopped because of side effects. Some had increases in heart rate, which researchers continue to watch. Dysesthesia, an altered or uncomfortable sense of touch on the skin, was reported more often than with placebo, mostly at higher doses. Because the drug is still investigational, its full side effect profile is not yet known. Anyone with health questions should talk to a qualified clinician.

Low blood sugar: The risk may rise when it is combined with insulin or other diabetes drugs that lower blood sugar.
Class cautions: Researchers watch for issues seen with approved GLP-1 drugs, such as pancreatitis, gallbladder problems and the thyroid C-cell tumors seen in rodent studies of those drugs.
Nutrition and muscle: A large drop in appetite can make it hard to eat enough protein and nutrients, and in this drug class part of the weight lost is lean tissue.
Pregnancy and long-term use: There are no safety data in pregnancy, and no studies have followed people for many years.
Product content: Products sold online as retatrutide outside clinical trials may not contain what their labels say.